Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The FTC estimates that the final rule banning #noncompetes will lead to new business formation growing by 2.7% per year, resulting in more than 8,500 additional new businesses created each year. Learn more: https://t.co/uyHKiPihQg https://t.co/PVMRcLSBy2
(1/2) Health Care Antitrust Weekly: FTC Issues More Warning Letters for Orange Book Patent Listings; Physician Advocates Hail Noncompete Ban...
OPINION | The Case Against Noncompete Agreements...Last week, the U.S. Federal Trade Commission effectively tried to kill noncompete agreements. While some companies plan to challenge this, Rob Enderle argues it was the right decision to make. https://t.co/HllNCfckJF https://t.co/aw3uKmQWXS
The Federal Trade Commission (FTC) has recently issued warnings to pharmaceutical companies about the use of 'junk' patents to protect drugs like Novo Nordisk's Ozempic from generic competition, focusing on Orange Book Patent Listings. Concurrently, the FTC has enacted a momentous federal ban on nearly all noncompete agreements. This decision, expected to foster increased business formation by 2.7% annually, resulting in more than 8,500 additional new businesses each year, has significant implications for healthcare businesses, which are now reviewing their employment contracts due to their previous reliance on noncompetes.